Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients with Oesophageal Squamous Cell Cancer By Ogkologos - April 23, 2025 537 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a biomarker analysis from the RATIONALE-302 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR What to Know About At-Home DNA Tests for Detecting Cancer Risk May 24, 2022 The Mediterranean Diet October 30, 2020 Holiday Travel: 11 Things To Know Before Hitting The Road With... November 20, 2019 Exercising While Living With Peripheral Neuropathy: What People Diagnosed With Cancer... May 2, 2023 Load more HOT NEWS Tesco is making it even easier to support life-saving research FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid... Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus... Enhertu Marks First Targeted Therapy for HER2-Mutant Lung Cancer
